FDA allows Curis to resume testing cancer drug

(Reuters) - Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Enrolment for the study was halted after the death of a patient with advanced breast cancer, who experienced acute liver failure about a month after the drug, codenamed CUDC-427, was discontinued. Curis said it planned to continue testing the drug - including in combination with chemotherapy drug, capecitabine - in patients of a type of advanced breast cancer.



via Health News Headlines - Yahoo News http://ift.tt/1jPaVcv